Products 

& pipeline

EVG-001 is a kit for the preparation of Gallium-68 DOTATOC for use with PET-CT, currently under review by the FDA. If approved, EVG-001 can be used in conjunction with a PET scan to stage and localize neuroendocrine tumors in adults and children.

‍

Our EVG321 RLTs are highly specific peptide vectors, which bind to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker. For small cell lung carcinoma, CCK2R is expressed with a frequency of 20%-50%. 68Ga-EVG321 has shown encouraging early clinical results (Di Santo G et al., 2024). If successful, EVG321 could offer new hope to patients with small cell lung cancer.

EVG311 molecularly targeted tracer binds to a glial cell surface molecule for the treatment of glioblastoma (GBM) and other glial tumors. Effective treatment of GBM is one of the biggest unmet needs in oncology. The 5-year survival rate for GBM is 5.5% in the US, and annually about 13,000 patients in the US receive a GBM diagnosis.

Our EVG332 radiotracer targets a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). The 5-year survival rate for PDAC patients is 11.5%, and significantly lower for patients presenting with distant metastatic disease (3.1%). More than 50% of patients have distant disease at the time of diagnosis. Annually about 33,000 patients in the US receive a distant PDAC diagnosis.

EVG341 molecularly targeted tracer binds to a cancer-specific hormone receptor for the treatment of invasive lobular breast cancer (ILC). ILC represents approximately 10% of all advanced breast cancers, and due to its diffuse and multi-focal nature is difficult to detect. This characteristic also makes breast-conserving surgery more challenging, and its 5-year survival rate drops to 22%. Up to 65% of patients with lobular breast cancer require a second surgery.